Review by a blinded independent radiology review committee (IRC) has confirmed the progression-free survival (PFS) results from the phase II CABOSUN trial, which compares first-line cabozantinib with sunitinib in patients with advanced renal cell carcinoma (RCC). Cabozantinib demonstrated a clinically meaningful and statistically significant reduction in the rate of disease progression or death as measured by PFS. The manufacturer, Ipsen plans to submit the regulatory dossier for cabozantinib as a first-line treatment for advanced renal cell carcinoma in Europe in the third quarter of 2017.
Cabozantinib significantly improves progression free survival compared to sunitinib as first-line treatment for advanced kidney cancer
21 Jun 2017
Most used tags
renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo sunitinib Sutent progression-free survival cabozantinib biomarkers NHS England Cabometyx ipilimumab pembrolizumab COVID-19 cancer survival axitinib VEGF inhibitors non-clear cell kidney cancer Inlyta coronavirus Yervoy risk factors Keytruda metastases adjuvant therapy biological markers papillary RCC targeted therapy everolimus Afinitor ASCO cancer outcomes first-line treatment NICE partial nephrectomyArchives
- 2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec